Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.
Metrics to compare | 4503 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4503PeersSector | |
---|---|---|---|---|
P/E Ratio | 149.1x | 17.7x | −0.6x | |
PEG Ratio | −1.81 | 0.47 | 0.00 | |
Price / Book | 1.9x | 1.5x | 2.6x | |
Price / LTM Sales | 1.9x | 2.1x | 3.1x | |
Upside (Analyst Target) | 15.2% | 8.3% | 57.6% | |
Fair Value Upside | Unlock | 15.8% | 7.3% | Unlock |